Posts by Anna Jurczynska

Updated rules for clinical development of vaccines

26/04/2018 EMA launches public consultation on revised guideline on clinical evaluation of vaccines The European Medicines Agency (EMA) has released a revised guideline on the clinical evaluation of vaccines for a six-month public consultation. Stakeholders are invited to send their comments by 30 October 2018 to vwp@ema.europa.eu using the template provided in the guideline. Vaccination is one of the greatest breakthroughs in modern medicine.…

Read More

Civil society representatives wanted…

Civil society representatives wanted for EMA’s Management Board and Pharmacovigilance Committee 30/04/2018 Submission deadline is 8 June 2018 The European Commission has launched a call for expressions of interest for civil society representatives to join the Management Board of the European Medicines Agency (EMA), as well as the Agency’s Pharmacovigilance Risk Assessment Committee(PRAC). This is an opportunity for civil society representatives to…

Read More

EMA 2017 annual report published

02/05/2018 Report highlights major achievements and includes key figures The 2017 annual report published today provides an overview of the work of the European Medicines Agency (EMA) and highlights last year’s major achievements in protecting and promoting public and animal health in the European Union (EU). EMA’s annual report draws attention to some of the Agency’s main…

Read More

The PharmaTrain Syllabus for Pharmaceutical Medicine / Medicines Development Science (Version 2.0) 2018

To all IFAPP National Member Associations (NMAs) and Individual Affiliates  We are pleased to introduce the 2018 PharmaTrain Syllabus (2018 Syllabus).*  IFAPP, The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine, together with The PharmaTrain Federation (PTF) and The Faculty of Pharmaceutical Medicine of the UK Royal Colleges of Physicians (FPM)  jointly sponsored…

Read More

I AM IFAPP: JOHANNA SCHENK

Today we are starting a new section on the IFAPP website, recognizing the value and professionalism of relevant members of IFAPP who have greatly contributed to the growth and development of our Federation: “I am IFAPP”. The first person to talk to all of us and comment on her experience is Dr. Johanna Schenk, Past…

Read More

FDA: E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)

Guidance for Industry INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of trial subjects are protected, consistent with the principles that have their…

Read More

Support for industry on clinical data publication

Agendas, meeting reports, presentations, question-and-answer documents and available video recordings are provided on the meeting pages. Micro, small and medium-sized enterprises Micro, small and medium-sized enterprises (SMEs) are entitled to a free redaction tool license valid for a period of 12 months to allow companies enough time to prepare the final redacted version. The application…

Read More

EMA: Human medicines highlights 2017

The European Medicines Agency (EMA) publishes information on the volume and outcome of marketing authorization and post-authorisation applications for human and veterinary medicines that it evaluates. Click the link below to view the report. ema human medicines highlights 2017 This document was originally posted by the EMA here. 

Read More

New tracking tool for EMA’s relocation to Amsterdam

05/03/2018 New tracking tool for EMA’s relocation to Amsterdam Tool gives transparent overview of main milestones and work stream deliverables*   The European Medicines Agency (EMA) has published a new tool showing the main milestones and deliverables for the Agency’s move to Amsterdam. Because of its important role to safeguard public and animal health in…

Read More

Regulatory information – adjusted fees for applications to EMA from 1 April 2018

05/03/2018 Regulatory information – adjusted fees for applications to EMA from 1 April 2018 Fees expected to increase by 1.7% The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2018 Every year, the European Commission adopts…

Read More